Randomised Controlled Trial Of Two Doses Of Heparin In Cerebral Venous Thrombosis

Cerebral venous thrombosis accounts for 10-20% of strokes in the young in India. Over the past decade, heparin has become the mainstay of treatment of cerebral venous thrombosis. The conventional doses of heparin require strict monitoring of activated partial thromboplastin time. Effic...

Full description

Bibliographic Details
Main Authors: Sarma G.K, Nagaraja D
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2005-01-01
Series:Annals of Indian Academy of Neurology
Online Access:http://www.annalsofian.org/article.asp?issn=0972-2327;year=2005;volume=8;issue=4;spage=233;epage=236;aulast=Sarma;type=0
_version_ 1819208664034050048
author Sarma G.K
Nagaraja D
author_facet Sarma G.K
Nagaraja D
author_sort Sarma G.K
collection DOAJ
description Cerebral venous thrombosis accounts for 10-20% of strokes in the young in India. Over the past decade, heparin has become the mainstay of treatment of cerebral venous thrombosis. The conventional doses of heparin require strict monitoring of activated partial thromboplastin time. Efficacy of low doses of heparin in cerebral venous thrombosis has already been studied. Objective: The present study compared the low dose heparin to medium dose of heparin in cerebral venous thrombosis. Methods: A prospective, randomized controlled study including consecutive patients was conducted in the department of Neurology, a tertiary referral center in India from 1996 to 1998. Patients with cerebral venous thrombosis confirmed clinically and by neuroimaging were randomized to receive low dose (2500 units TID) or medium dose (5000 units TID) heparin. All patients were assessed periodically until discharge or death. Outcome was assessed using modified Rankin scale (good outcome <3, poor outcome 3 3). Patients who deteriorated without increase of hemorrhage or developed deep venous thrombosis were given higher doses of heparin. Results: Twenty-nine patients were randomized into each group. There was no increase or additional hemorrhage in either group. Five patients in the low dose group required increase in heparin dose (to 5000 units TID) due to deterioration. Good outcome was seen in 89% on medium dose and 44.8% on low dose heparin (p<0.05). Conclusions: the randomized controlled trial from an Indian center demonstrated that medium dose regimen of heparin is better than low dose regimen and also safe in the treatment of cerebral venous thrombosis.
first_indexed 2024-12-23T05:42:59Z
format Article
id doaj.art-e878379a648b442da45dd798e33ab63c
institution Directory Open Access Journal
issn 0972-2327
1998-3549
language English
last_indexed 2024-12-23T05:42:59Z
publishDate 2005-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Annals of Indian Academy of Neurology
spelling doaj.art-e878379a648b442da45dd798e33ab63c2022-12-21T17:58:08ZengWolters Kluwer Medknow PublicationsAnnals of Indian Academy of Neurology0972-23271998-35492005-01-0184233236Randomised Controlled Trial Of Two Doses Of Heparin In Cerebral Venous ThrombosisSarma G.KNagaraja DCerebral venous thrombosis accounts for 10-20% of strokes in the young in India. Over the past decade, heparin has become the mainstay of treatment of cerebral venous thrombosis. The conventional doses of heparin require strict monitoring of activated partial thromboplastin time. Efficacy of low doses of heparin in cerebral venous thrombosis has already been studied. Objective: The present study compared the low dose heparin to medium dose of heparin in cerebral venous thrombosis. Methods: A prospective, randomized controlled study including consecutive patients was conducted in the department of Neurology, a tertiary referral center in India from 1996 to 1998. Patients with cerebral venous thrombosis confirmed clinically and by neuroimaging were randomized to receive low dose (2500 units TID) or medium dose (5000 units TID) heparin. All patients were assessed periodically until discharge or death. Outcome was assessed using modified Rankin scale (good outcome <3, poor outcome 3 3). Patients who deteriorated without increase of hemorrhage or developed deep venous thrombosis were given higher doses of heparin. Results: Twenty-nine patients were randomized into each group. There was no increase or additional hemorrhage in either group. Five patients in the low dose group required increase in heparin dose (to 5000 units TID) due to deterioration. Good outcome was seen in 89% on medium dose and 44.8% on low dose heparin (p<0.05). Conclusions: the randomized controlled trial from an Indian center demonstrated that medium dose regimen of heparin is better than low dose regimen and also safe in the treatment of cerebral venous thrombosis.http://www.annalsofian.org/article.asp?issn=0972-2327;year=2005;volume=8;issue=4;spage=233;epage=236;aulast=Sarma;type=0
spellingShingle Sarma G.K
Nagaraja D
Randomised Controlled Trial Of Two Doses Of Heparin In Cerebral Venous Thrombosis
Annals of Indian Academy of Neurology
title Randomised Controlled Trial Of Two Doses Of Heparin In Cerebral Venous Thrombosis
title_full Randomised Controlled Trial Of Two Doses Of Heparin In Cerebral Venous Thrombosis
title_fullStr Randomised Controlled Trial Of Two Doses Of Heparin In Cerebral Venous Thrombosis
title_full_unstemmed Randomised Controlled Trial Of Two Doses Of Heparin In Cerebral Venous Thrombosis
title_short Randomised Controlled Trial Of Two Doses Of Heparin In Cerebral Venous Thrombosis
title_sort randomised controlled trial of two doses of heparin in cerebral venous thrombosis
url http://www.annalsofian.org/article.asp?issn=0972-2327;year=2005;volume=8;issue=4;spage=233;epage=236;aulast=Sarma;type=0
work_keys_str_mv AT sarmagk randomisedcontrolledtrialoftwodosesofheparinincerebralvenousthrombosis
AT nagarajad randomisedcontrolledtrialoftwodosesofheparinincerebralvenousthrombosis